Vaccines made from recombinant yeast cells

Hilleman, Maurice R.; Ellis, Ronald W.

doi:10.1016/0264-410x(86)90040-x

Cited by 18 publications

(6 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar serum-derived vaccines were then produced from various manufacturers, such as Hepavax-B (Green Cross, Korea), Hepaccine-B (Cheil, Korea), and GCC VAC (Green Cross Corporation, Osaka) ( Table 1). Limitations given by the supply of human plasma from chronically infected patients, and the risk associated with human-derived products due to contaminating proteins and the potential presence of other pathogens transmitted by blood, in particular a non-A non-B hepatitis virus, confronted the use of human plasma-derived HBsAg SVP vaccines [121][122][123]. Safety concerns about products from human sources, together with the advances in recombinant DNA technology and biotechnology, led to the development of recombinant hepatitis B vaccines.…”

Section: The First Vaccine Generation Against Hbv: Vaccine Derived Frmentioning

confidence: 99%

Hepatitis B Virus (HBV) Subviral Particles as Protective Vaccines and Vaccine Platforms

Jeevan-Raj

Netter

2020

Viruses

View full text Add to dashboard Cite

Hepatitis B remains one of the major global health problems more than 40 years after the identification of human hepatitis B virus (HBV) as the causative agent. A critical turning point in combating this virus was the development of a preventative vaccine composed of the HBV surface (envelope) protein (HBsAg) to reduce the risk of new infections. The isolation of HBsAg sub-viral particles (SVPs) from the blood of asymptomatic HBV carriers as antigens for the first-generation vaccines, followed by the development of recombinant HBsAg SVPs produced in yeast as the antigenic components of the second-generation vaccines, represent landmark advancements in biotechnology and medicine. The ability of the HBsAg SVPs to accept and present foreign antigenic sequences provides the basis of a chimeric particulate delivery platform, and resulted in the development of a vaccine against malaria (RTS,S/AS01, MosquirixTM), and various preclinical vaccine candidates to overcome infectious diseases for which there are no effective vaccines. Biomedical modifications of the HBsAg subunits allowed the identification of strategies to enhance the HBsAg SVP immunogenicity to build potent vaccines for preventative and possibly therapeutic applications. The review provides an overview of the formation and assembly of the HBsAg SVPs and highlights the utilization of the particles in key effective vaccines.

show abstract

Section: The First Vaccine Generation Against Hbv: Vaccine Derived Frmentioning

confidence: 99%

Hepatitis B Virus (HBV) Subviral Particles as Protective Vaccines and Vaccine Platforms

Jeevan-Raj

Netter

2020

Viruses

View full text Add to dashboard Cite

show abstract

“…Antibody-based assays are not suited for this purpose. The method described herein fulfils this need and may have wide applicability considering the large number of laboratories involved in the production of HBsAg in yeast (Hilleman and Ellis, 1986).…”

Section: Discussionmentioning

confidence: 86%

Biochemical estimation of hepatitis B surface antigen in recombinant yeast

Wingfield

Graber

Payton

1987

Yeast

View full text Add to dashboard Cite

Purified recombinant hepatitis B surface antigen separated on polyacrylamide gels in the presence of sodium dodecyl sulphate has a very low staining index with Coomassie blue relative to a number of standard proteins. In contrast the protein stains better than average with silver nitrate. This property has been used to develop a semi-quantitative method of estimation of recombinant surface antigen in extracts of Saccharomyces cerevisiae producing this protein. The method can be used to follow purification protocols. It is quick, simple and since it measures the surface antigen biochemically, is independent of the aggregation state or conformation of the protein, a factor which can affect enzyme-linked immunoassays which rely on antigen-antibody interactions.

show abstract

“…Confusion and illogical fears exist about the RAS sc gene and the Ty element of yeasts (6). Fears have been expressed for possible sensitization of vaccinees.…”

Section: P O L Y P E P T I D E V a C C I N E Smentioning

confidence: 99%

New vaccines against hepatitis B

Papaevangelou

Roumeliotou‐Karayannis

1987

Eur J Epidemiol

View full text Add to dashboard Cite

The high cost and limited availability of the plasma-derived hepatitis B vaccines have prevented their widespread use, especially in the less developed areas where they are needed most. Hepatitis B vaccines produced by recombinant technology seem to offer a solution to these difficulties. Studies reported up to now confirmed the safety of this vaccine. Immunogenicity studies in various population groups showed that seroconversion rates and antibody titres are comparable to plasma vaccine. In assessing the efficacy of the vaccine, information concerning the quality of the anti-HBs induced should complement these data. Potential live vaccines using recombinant vaccinia viruses have been constructed for hepatitis B. Preliminary studies in rabbits and chimpanzees indicated the feasibility of future using a recombinant vaccinia virus. Chemically synthesized polypeptides corresponding to relevant epitopes of HBsAg may be useful as synthetic vaccines offering the advantages of a cheap viral immunogen free from irrelevant antigenic determinants. Finally preliminary studies for an idiotypic vaccine have already been reported.

show abstract

Vaccines made from recombinant yeast cells

Cited by 18 publications

References 11 publications

Hepatitis B Virus (HBV) Subviral Particles as Protective Vaccines and Vaccine Platforms

Hepatitis B Virus (HBV) Subviral Particles as Protective Vaccines and Vaccine Platforms

Biochemical estimation of hepatitis B surface antigen in recombinant yeast

New vaccines against hepatitis B

Contact Info

Product

Resources

About